Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Tolerating False Positives: Amylyx, FDA, And The Legal Case For Broad Regulatory Flexibility
Sep 09 2022
•
By
Sarah Karlin-Smith
Regulatory flexibility was a central theme at Amylyx’s second-chance FDA advisory panel for its ALS drug. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers